Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.

The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.

Summary aggregated from MarketWatch's public RSS feed. The full reporting belongs to MarketWatch — please read it on their site.